{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:52:54Z","timestamp":1791219174489,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","award":["202103100568"],"award-info":[{"award-number":["202103100568"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472810"],"award-info":[{"award-number":["81472810"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972864"],"award-info":[{"award-number":["81972864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111684","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:59:35Z","timestamp":1708052375000},"page":"111684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma"],"prefix":"10.1016","volume":"129","author":[{"given":"Xiaohan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9180-2521","authenticated-orcid":false,"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2024.111684_b0005","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.intimp.2024.111684_b0010","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer I"},{"issue":"2","key":"10.1016\/j.intimp.2024.111684_b0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9687","key":"10.1016\/j.intimp.2024.111684_b0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.intimp.2024.111684_b0025","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.intimp.2024.111684_b0030","first-page":"990","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer REPLY","volume":"380","author":"Antonia","year":"2019","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.intimp.2024.111684_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2024.111684_b0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2020.04.047","article-title":"Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab","volume":"149","author":"Offin","year":"2020","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.intimp.2024.111684_b0050","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.intimp.2024.111684_b0055","doi-asserted-by":"crossref","first-page":"34300","DOI":"10.18632\/oncotarget.5549","article-title":"Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.111684_b0060","first-page":"10","article-title":"Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.intimp.2024.111684_b0065","article-title":"Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC","volume":"40","author":"Naidoo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0070","article-title":"Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines-Basel"},{"issue":"6","key":"10.1016\/j.intimp.2024.111684_b0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.intimp.2024.111684_b0080","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazi\u00e8res","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","article-title":"Original Research Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations","volume":"167","author":"Riudavets","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2024.111684_b0090","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jtho.2020.12.020","article-title":"Role of Consolidation Durvalumab in Patients With and Mutant Unresectable Stage III NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2022.01.020","article-title":"Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer","volume":"166","author":"Schmid","year":"2022","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.111684_b0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0105","article-title":"Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdz453.002","article-title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.intimp.2024.111684_b0115","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.intimp.2024.111684_b0120","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.intimp.2024.111684_b0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"15","key":"10.1016\/j.intimp.2024.111684_b0130","article-title":"CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1\u2013N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial","volume":"38","author":"Wu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.intimp.2024.111684_b0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8531","article-title":"A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation","volume":"35","author":"Xing","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.intimp.2024.111684_b0145","first-page":"138","article-title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA","volume":"43","author":"Groh\u00e9","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"1","key":"10.1016\/j.intimp.2024.111684_b0150","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1016\/j.cllc.2018.08.017","article-title":"A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)","volume":"20","author":"Akamatsu","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2024.111684_b0155","first-page":"612","article-title":"SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer (vol 37, pg 97, 2019)","volume":"37","author":"Pennell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2024.111684_b0160","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111684_b0165","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: What does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J Thorac Cardiov Sur"},{"issue":"2","key":"10.1016\/j.intimp.2024.111684_b0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.111684_b0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canrad.2019.09.007","article-title":"Role of immunotherapy in locally advanced non-small cell lung cancer","volume":"24","author":"Levy","year":"2020","journal-title":"Cancer Radiother"},{"issue":"3","key":"10.1016\/j.intimp.2024.111684_b0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12325-019-0876-4","article-title":"Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes","volume":"36","author":"Rajappa","year":"2019","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.intimp.2024.111684_b0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"Jama Oncol"},{"key":"10.1016\/j.intimp.2024.111684_b0190","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182464","article-title":"Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis","volume":"39","author":"Hu","year":"2019","journal-title":"Bioscience Rep"},{"issue":"7","key":"10.1016\/j.intimp.2024.111684_b0195","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-018-1172-x","article-title":"Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study","volume":"35","author":"Nishimoto","year":"2018","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.intimp.2024.111684_b0200","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"10.1016\/j.intimp.2024.111684_b0205","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1396403","article-title":"Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1\/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials","volume":"7","author":"Huang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.intimp.2024.111684_b0210","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.intimp.2024.111684_b0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0943-4","article-title":"Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma","volume":"14","author":"Song","year":"2016","journal-title":"J Transl Med"},{"issue":"25","key":"10.1016\/j.intimp.2024.111684_b0220","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.intimp.2024.111684_b0225","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6230","key":"10.1016\/j.intimp.2024.111684_b0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.intimp.2024.111684_b0235","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.intimp.2024.111684_b0240","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/cam4.3649","article-title":"Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Cancer Med-Us"},{"issue":"11","key":"10.1016\/j.intimp.2024.111684_b0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.111684_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2017.11.009","article-title":"Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions","volume":"115","author":"Soo","year":"2018","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2024.111684_b0255","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"Mutations and Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.intimp.2024.111684_b0260","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","article-title":"Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer","volume":"16","author":"Hwang","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.111684_b0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2024.111684_b0270","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0835-x","article-title":"Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?","volume":"21","author":"Desai","year":"2019","journal-title":"Curr Oncol Rep"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:43:25Z","timestamp":1769229805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"alternative-id":["S1567576924002029"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111684","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111684"}}